Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid for prevention of bone loss after bariatric surgery
2019-001650-26Phase 4Completed
- Sponsor
- Hospital of South West Jutland
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of zoledronic acid in class III obesity and osteoporosis, sponsored by Hospital of South West Jutland. Primary endpoint: Bone mineral density at proximal femur. Started Sep 2019; status: completed.
02
Drugs
zoledronic acid
03
Conditions
class III obesityosteoporosis
Beyond the preview
Go deeper on 2019-001650-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001650-26.